CN105999368A - Epidermal growth factor compound wet wound dressing and preparation method thereof - Google Patents
Epidermal growth factor compound wet wound dressing and preparation method thereof Download PDFInfo
- Publication number
- CN105999368A CN105999368A CN201610602709.8A CN201610602709A CN105999368A CN 105999368 A CN105999368 A CN 105999368A CN 201610602709 A CN201610602709 A CN 201610602709A CN 105999368 A CN105999368 A CN 105999368A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- epidermal growth
- parts
- dressing
- combined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention belongs to the technical field of biological materials and particularly relates to an epidermal growth factor compound wet wound dressing and a preparation method thereof. The epidermal growth factor compound wet wound dressing is prepared from the following components in parts by weight: 0.1-0.7 part of epidermal growth factor, 3-10 parts of sodium alginate, 3-10 parts of chitosan, 3-10 parts of vegetable starch, 0.1-0.5 part of Ag<+> and 10-50 parts of injection water. The prepared epidermal growth factor compound wet wound dressing provides wet healing condition for wound healing and is excellent in healing effect.
Description
Technical field
The invention belongs to technical field of biological materials, be specifically related to a kind of epidermal growth factor and be combined Moist wound
Dressing and preparation method thereof.
Background technology
Along with the development of modern invasive techniques, wound dressing not only has the effect of flap coverage, prior
It it is the function with wound healing.From the sixties in 20th century, numerous scholars pass through substantial amounts of wound surface
Experimentation and clinical practice prove that wound dressing has the function of wound healing, currently in wound dressing
Research and development in the most preferably implement " wet environment " theoretical, play the treatment advantage that the traditional Chinese medical science is traditional simultaneously,
It will be the direction of following novel wound dressing research and development.
In recent years, the proposition of the innovation of biomaterials art and " wet environment healing " theory is to wound dressing
Development produce great pushing effect, various wound dressings emerge in an endless stream, and wound dressing is according to its material
Difference is divided into traditional dressing, biological dressing, synthetic dressing and somatomedin dressing etc..These wounds are applied
Material is all relative closure and wet environment, its wound healing utilizing the characteristic of different materials to keep wound surface
Mechanism of action be: create wound surface low-oxygen environment, promote blood capillary generation；Be conducive to slough
Removing with toxin；Strengthening somatomedin and the interaction of target cell；Avoid newborn epithelial tissue and dressing
Adhesion, alleviates patient suffering.Therefore wound dressing is possible not only to shorten wound healing time, reduces resource
Waste, and medical workload can be substantially reduced, meet patient requests.
The multiplex cotton of normal gauze dressing or synthetic, processing technology is relatively simple, is the most most widely used
Dressing.But traditional gauze class dressing has many shortcomings, such as easy breed bacteria, wound fluid is easily with dry
Form crust after dry dermal tissue adhesion, hinder epithelization process etc.；After wound surface and gauze adhesion, change dressings and take off
Easily cause when rising and have an intense pain, even bring secondary insult.
Biological dressing has good biocompatibility and biodegradability, can be the most anti-when more change dressings
Only adhesion, it is to avoid the formation of secondary insult.Additionally, biological dressing also has good cell absorbability,
Be conducive to sticking and growing of cell, reduce infection rate, thus improve quality and the speed of wound healing.Raw
Thing dressing is divided into animal skins dressing and non-animal skin dressing.Animal skins dressing include autologous skin, alloskin,
Xenogenesis skin；Non-animal skin dressing mainly includes collagen, chitin (chitosan), Sargassum acids etc..
Synthetic dressing, aerogel dressing is the dressing as substrate with glycerol or water, horizontal by hydrophilic polymer
To the 3 D stereo network structure being formed by connecting, membranaceous and unformed two kinds of forms are broadly divided into it.This type of applies
The main mechanism of material is autologous debridement, refers in moist environment, relies on the collagen in wound surface self transudate
Protein degradation enzyme decomposes downright bad material, thus promotes new vessels to generate, accelerates epithelial cell growth.
Along with the development of biomolecule technology, somatomedin wound dressing becomes art of wound dressings development gradually
New lover.Somatomedin wound dressing can not only overcome the shortcoming that traditional dressing performance is single, and because making a living
The addition of the long factor also makes dressing add wound healing, improve new effect of wound healing effect.
Summary of the invention
Invention broadly provides a kind of epidermal growth factor and be combined moist wound dressings and preparation method thereof, for
Wound healing provides wet union condition, and healing effect is good.Its technical scheme is as follows:
A kind of epidermal growth factor is combined moist wound dressings, and it includes the component of following weight portion: epidermis is raw
Long factor 0.1-0.7 part, sodium alginate 3-10 part, chitosan 3-10 part, plant amylum 3-10 part, Ag+0.1-0.5
Part and water for injection 10-50 part.
Preferably, described epidermal growth factor is combined moist wound dressings, and it includes the component of following weight portion:
Epidermal growth factor 0.5 part, sodium alginate 5 parts, chitosan 5 parts, plant amylum 5 parts, Ag+0.1 part
With water for injection 25 parts.
Preferably, described epidermal growth factor is external recombinant human epidermal growth factor.
Preferably, described plant amylum is potato starch and/or corn starch.
Preferably, the deacetylation of described chitosan is 85-100%.
A kind of epidermal growth factor is combined the preparation method of moist wound dressings, and it comprises the following steps:
(1) weigh sodium alginate, epidermal growth factor mix homogeneously by formula ratio, obtain mixed powder；
(2) chitosan of formula ratio, plant amylum, Ag are weighed+With water mix homogeneously, obtain mixed liquor；
(3) mixed powder of step (1) is added in the mixed liquor of step (2), be sufficiently stirred for；
(4) mixture that step (3) obtains is carried out spraying stirring reaction and prepares homogeneous moist dressing；
(5) by subpackage after moist dressing sterilizing.
Using above-mentioned epidermal growth factor to be combined moist wound dressings and preparation method thereof, the present invention has following
Advantage:
External recombinant human epidermal growth factor is added in this case, improves wound healing effect；With the addition of argent from
Son can be wound surface sterilizing, reduces traumatic infection, wound healing；Both plant amylum and chitosan are one
Coupling can be combined under fixed condition and form composite microporous structure, contribute to forming wet environment, it is provided that wet union
Condition；Sodium alginate can effectively pin moisture, maintains wet union microenvironment, the healing speed of acceleration of wound
Degree.Multiple components is combined, reaches splendid wound healing effect by the synergism between medicine.
Specific embodiment
Embodiment 1
A kind of epidermal growth factor is combined moist wound dressings, and it includes the component of following weight portion: epidermis is raw
The long factor 0.5 part, sodium alginate 5 parts, chitosan 5 parts, plant amylum 5 parts, Ag+0.1 part and injection
With 25 parts of water.
Wherein said epidermal growth factor is external recombinant human epidermal growth factor, and described plant amylum is Ma Ling
Sweet potato starch, the deacetylation of chitosan is 85%.
Above-mentioned epidermal growth factor is combined the preparation method of moist wound dressings:
(1) weigh sodium alginate, epidermal growth factor mix homogeneously by formula ratio, obtain mixed powder；
(2) chitosan of formula ratio, plant amylum, Ag are weighed+With water mix homogeneously, obtain mixed liquor；
(3) mixed powder of step (1) is added in the mixed liquor of step (2), be sufficiently stirred for；
(4) mixture that step (3) obtains is carried out spraying stirring reaction and prepares homogeneous moist dressing；
(5) by subpackage after moist dressing sterilizing.
Embodiment 2
A kind of epidermal growth factor is combined moist wound dressings, and it includes the component of following weight portion: epidermis is raw
The long factor 0.1 part, sodium alginate 3 parts, chitosan 10 parts, plant amylum 10 parts, Ag+0.5 part and injection
With 10 parts of water.
Wherein said epidermal growth factor is external recombinant human epidermal growth factor, and described plant amylum is Semen Maydis
Starch, the deacetylation of chitosan is 90%.
Above-mentioned epidermal growth factor is combined the preparation method of moist wound dressings:
(1) weigh sodium alginate, epidermal growth factor mix homogeneously by formula ratio, obtain mixed powder；
(2) chitosan of formula ratio, plant amylum, Ag are weighed+With water mix homogeneously, obtain mixed liquor；
(3) mixed powder of step (1) is added in the mixed liquor of step (2), be sufficiently stirred for；
(4) mixture that step (3) obtains is carried out spraying stirring reaction and prepares homogeneous moist dressing；
(5) by subpackage after moist dressing sterilizing.
Embodiment 3
A kind of epidermal growth factor is combined moist wound dressings, and it includes the component of following weight portion: epidermis is raw
The long factor 0.7 part, sodium alginate 10 parts, chitosan 3 parts, plant amylum 8 parts, Ag+0.3 part and injection
With 50 parts of water.
Wherein said epidermal growth factor is external recombinant human epidermal growth factor, and described plant amylum is Semen Maydis
Starch, the deacetylation of chitosan is 95%.
Above-mentioned epidermal growth factor is combined the preparation method of moist wound dressings:
(1) weigh sodium alginate, epidermal growth factor mix homogeneously by formula ratio, obtain mixed powder；
(2) chitosan of formula ratio, plant amylum, Ag are weighed+With water mix homogeneously, obtain mixed liquor；
(3) mixed powder of step (1) is added in the mixed liquor of step (2), be sufficiently stirred for；
(4) mixture that step (3) obtains is carried out spraying stirring reaction and prepares homogeneous moist dressing；
(5) by subpackage after moist dressing sterilizing.
Embodiment 4
A kind of epidermal growth factor is combined moist wound dressings, and it includes the component of following weight portion: epidermis is raw
The long factor 0.3 part, sodium alginate 7 parts, chitosan 7 parts, plant amylum 10 parts, Ag+0.4 part and injection
With 40 parts of water.
Wherein said epidermal growth factor is external recombinant human epidermal growth factor, and described plant amylum is Ma Ling
Sweet potato starch and the mixing of corn starch arbitrary proportion, the deacetylation of chitosan is 100%.
Above-mentioned epidermal growth factor is combined the preparation method of moist wound dressings:
(1) weigh sodium alginate, epidermal growth factor mix homogeneously by formula ratio, obtain mixed powder；
(2) chitosan of formula ratio, plant amylum, Ag are weighed+With water mix homogeneously, obtain mixed liquor；
(3) mixed powder of step (1) is added in the mixed liquor of step (2), be sufficiently stirred for；
(4) mixture that step (3) obtains is carried out spraying stirring reaction and prepares homogeneous moist dressing；
(5) by subpackage after moist dressing sterilizing.
Repair in trauma is tested
1. test material: SD rat 70 only makes repair in trauma model, is randomly divided into 6 groups, often group 10,
I.e. A, B, C, D, E, F group.
2.A group uses in embodiment 1 that the epidermal growth factor of preparation is combined moist wound dressings, B group uses list
The chitosan dressing of one, C group use single sodium alginate dressing, D group uses single epidermal growth factor
Dressing, E group use single plant amylum adjuvant, F group is used existing gauze and covered, and observe wound surface hemostasis
And repair time record.
3. experimental result, utilizes mean value ± variance to calculate each group of bleeding stopping period, illustrates each group with non parametric tests
The difference of haemostatic effect, best results in the haemostatic effect 6 groups of result display A group, refers to table 1.
1 six groups of material haemostatic effects of table compare
It will be apparent to those skilled in the art that can technical scheme as described above and design, make it
Its various corresponding changes and deformation, and all these changes and deformation all should belong to present invention power
Within the protection domain that profit requires.
Claims (6)
1. epidermal growth factor is combined a moist wound dressings, and it includes the component of following weight portion: epidermis
Somatomedin 0.1-0.7 part, sodium alginate 3-10 part, chitosan 3-10 part, plant amylum 3-10 part, Ag+
0.1-0.5 part and water for injection 10-50 part.
Epidermal growth factor the most according to claim 1 is combined moist wound dressings, and it includes following heavy
Amount part component: epidermal growth factor 0.5 part, sodium alginate 5 parts, chitosan 5 parts, plant amylum 5 parts,
Ag+0.1 part and water for injection 25 parts.
Epidermal growth factor the most according to claim 1 is combined moist wound dressings, it is characterised in that:
Described epidermal growth factor is external recombinant human epidermal growth factor.
Epidermal growth factor the most according to claim 1 is combined moist wound dressings, it is characterised in that:
Described plant amylum is potato starch and/or corn starch.
Epidermal growth factor the most according to claim 1 is combined moist wound dressings, it is characterised in that:
The deacetylation of chitosan is 85-100%.
6. the epidermal growth factor described in an any one of claim 1-5 is combined the preparation of moist wound dressings
Method, it is characterised in that: it comprises the following steps:
(1) weigh sodium alginate, epidermal growth factor mix homogeneously by formula ratio, obtain mixed powder；
(2) chitosan of formula ratio, plant amylum, Ag are weighed+With water mix homogeneously, obtain mixed liquor；
(3) mixed powder of step (1) is added in the mixed liquor of step (2), be sufficiently stirred for；
(4) mixture that step (3) obtains is carried out spraying stirring reaction and prepares homogeneous moist dressing；
(5) by subpackage after moist dressing sterilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610602709.8A CN105999368A (en) | 2016-07-28 | 2016-07-28 | Epidermal growth factor compound wet wound dressing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610602709.8A CN105999368A (en) | 2016-07-28 | 2016-07-28 | Epidermal growth factor compound wet wound dressing and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105999368A true CN105999368A (en) | 2016-10-12 |
Family
ID=57113983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610602709.8A Pending CN105999368A (en) | 2016-07-28 | 2016-07-28 | Epidermal growth factor compound wet wound dressing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105999368A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108635622A (en) * | 2018-05-15 | 2018-10-12 | 杭州易敏生物医药科技有限公司 | New liquid gauze and its preparation method and application |
| WO2020113933A1 (en) * | 2018-12-03 | 2020-06-11 | 王丽萍 | Concentrate growth factor slow release freeze-dried membrane and preparation method therefor |
| CN112156225A (en) * | 2020-11-09 | 2021-01-01 | 唐长菱 | Chitosan or and algal polysaccharide composite biological matrix liquid dressing gel preparation and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101316618A (en) * | 2005-11-14 | 2008-12-03 | 株式会社大熊 | Sustained release film formulation for healing wound comprising epidermal growth factor |
| CN103071181A (en) * | 2013-02-01 | 2013-05-01 | 刘昌桂 | Hydrogel as well as preparation method and purpose of hydrogel |
| EP2878314A2 (en) * | 2012-07-27 | 2015-06-03 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies (A4TEC) | Polymeric mesh with selective permeability, for the repair and regeneration of tissues |
| CN104874010A (en) * | 2015-05-28 | 2015-09-02 | 深圳市源兴纳米医药科技有限公司 | Composite zinc silver antibacterial agent contained chitosan fiber dressing and preparation method thereof |
| CN105169460A (en) * | 2015-10-26 | 2015-12-23 | 广东泰宝医疗科技股份有限公司 | Magnetically therapeutic antibacterial haemostatic wound dressing and preparation method thereof |
-
2016
- 2016-07-28 CN CN201610602709.8A patent/CN105999368A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101316618A (en) * | 2005-11-14 | 2008-12-03 | 株式会社大熊 | Sustained release film formulation for healing wound comprising epidermal growth factor |
| EP2878314A2 (en) * | 2012-07-27 | 2015-06-03 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies (A4TEC) | Polymeric mesh with selective permeability, for the repair and regeneration of tissues |
| CN103071181A (en) * | 2013-02-01 | 2013-05-01 | 刘昌桂 | Hydrogel as well as preparation method and purpose of hydrogel |
| CN104874010A (en) * | 2015-05-28 | 2015-09-02 | 深圳市源兴纳米医药科技有限公司 | Composite zinc silver antibacterial agent contained chitosan fiber dressing and preparation method thereof |
| CN105169460A (en) * | 2015-10-26 | 2015-12-23 | 广东泰宝医疗科技股份有限公司 | Magnetically therapeutic antibacterial haemostatic wound dressing and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 夏照帆: "《烧伤外科学高级教程》", 31 March 2014, 人民军医出版社 * |
| 张流波等: "《医学消毒学最新进展》", 31 December 2015, 人民军医出版社 * |
| 戴德银等: "《实用新药特药手册》", 31 May 2012, 人民军医出版社 * |
| 潘英俊: "《粤厨宝典 点心篇》", 31 July 2014, 岭南美术出版社 * |
| 黄峻等: "《临床药物手册》", 31 January 2015, 上海科学技术出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108635622A (en) * | 2018-05-15 | 2018-10-12 | 杭州易敏生物医药科技有限公司 | New liquid gauze and its preparation method and application |
| WO2020113933A1 (en) * | 2018-12-03 | 2020-06-11 | 王丽萍 | Concentrate growth factor slow release freeze-dried membrane and preparation method therefor |
| CN112156225A (en) * | 2020-11-09 | 2021-01-01 | 唐长菱 | Chitosan or and algal polysaccharide composite biological matrix liquid dressing gel preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Czaja et al. | Microbial cellulose—the natural power to heal wounds | |
| Chiaoprakobkij et al. | Characterization and biocompatibility of bacterial cellulose/alginate composite sponges with human keratinocytes and gingival fibroblasts | |
| CN100443123C (en) | Medical chitosan dressing and its application | |
| CN102772819B (en) | Skin wound biological induced active dressing, preparation method and application thereof | |
| CN102526795A (en) | Chitosan-based styptic sponge and preparation method thereof | |
| CN108273122A (en) | A kind of recombined collagen hydrogel wound dressing and its preparation method and application | |
| KR20120092494A (en) | Degradation-stabilised, biocompatible collagen matrices | |
| CN101785873A (en) | Biocompatible bleed-stopping and bone healing promoting material and preparation method thereof | |
| CN105056285B (en) | It is a kind of can adhesion organization crack growth factor combine dressing and preparation method thereof | |
| CN104906626A (en) | Absorbable and degradable biocompatible hemostatic material and preparation method thereof | |
| CN109847088A (en) | Compound acellular dermal matrix biological dressing and preparation method thereof | |
| CN105999368A (en) | Epidermal growth factor compound wet wound dressing and preparation method thereof | |
| CN105797203A (en) | Alginate fiber based collagen sponge dressing and preparation method thereof | |
| CN111481735A (en) | Medical antibacterial wound-protecting hydrogel dressing and preparation method thereof | |
| CN1775302A (en) | Chitose-gelatine sponge wound dressing preparing method | |
| CN110152055A (en) | The functional drug that alginic acid amination derivative/bacteria cellulose nanocomposite gel is constructed is sustained medical dressing | |
| Thomas | A review of the physical, biological and clinical properties of a bacterial cellulose wound | |
| CN101450223A (en) | Hemostasia material based on chitosan, collagen and sodium cellulose glycolate and preparation method and use thereof | |
| CN202920687U (en) | Biological inductive active dressing for skin wound and medical dressing compound | |
| CN112190770B (en) | Degradable tooth extraction wound filling composition and preparation method and application thereof | |
| CN104069535B (en) | A kind of Preparation method and use of biological activity composite membrane bleeding-stopping dressing | |
| CN105194734A (en) | Chitosan-extracellular matrix tissue repairing membrane and preparation method thereof | |
| CN101797376A (en) | Preparation method of modified collagen film | |
| CN107970486A (en) | A kind of preparation method of chitosan-based compound hemostatic film | |
| CN105288709B (en) | wet wound dressing and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201106 Address after: 201613 No. 5, Jing Jing Road, Shanghai, Songjiang District Applicant after: SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY Co.,Ltd. Applicant after: SHANGHAI JIANHUA FINE BIOLOGICAL PRODUCTS Co.,Ltd. Address before: 200000, Huajing Road, Shanghai, Xuhui District, No. 1285 Applicant before: SHANGHAI JIANHUA FINE BIOLOGICAL PRODUCTS Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |
|
| RJ01 | Rejection of invention patent application after publication |